The UK and US have agreed to a major commercial pact that will maintain no import taxes on British medicine shipments entering the US market.
Key Provisions of the Deal
As part of the deal, the UK has agreed to increase expenditure on medicines through the NHS. This pledge guarantees that tariffs on these vital products will stay at nothing for a period of 36 months.
This agreement is in response to previous statements to hike import taxes on patented drug products, with figures mentioned as high as 100%.
"This deal between the UK strengthens the global environment for innovative medicines and establishes much-needed fairness to U.S.–U.K. medicine commerce," an announcement noted.
Commercial Significance
Drugs represent one of the UK's largest goods shipped to the America, which is easily the biggest market for leading British pharmaceutical firms.
Export figures reveal that in the 12 months to the end of last September, the UK exported medicines totaling £11.1bn to the US. This figure made up a significant portion of British export trade in that span.
"This deal secures work, stimulates investment and paves the way for the UK to emerge as a international leader for life sciences," a government official commented.
Specific UK Commitments
The agreement involves several key commitments from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it deems new therapies to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a goal to double total NHS spending on treatments from 0.3 percent of the national economy to 0.6 percent over the following ten-year period.
- Payback Limit: The percentage pharmaceutical firms must pay back to the NHS to stay within budget will be limited at 15%. Last year, repayments topped twenty percent.
Broader Context
The pact takes place against a ongoing tension between the drug companies and the UK government over medicine costs and NHS adoption.
This friction were heightened by assertions that American customers were paying significantly more for the equivalent treatments than consumers in the UK and Europe.
Recently, several large manufacturing plans in the UK have been halted or abandoned, while major expansions have been announced toward projects in the United States.
A senior figure acknowledged that the NHS had to spend more on medicines, noting that its budget allocation on drugs had decreased as a proportion of its overall budget over the last ten years.
